	US 12,227,585 B2
	Anti-BCMA antibody drug conjugate combination treatment for cancer
Sanjay Khandekar, Collegeville, PA (US); Patrick Mayes, Devon, PA (US); and Joanna Opalinska, Collegeville, PA (US)
Assigned to GlaxoSmithKline Intellectual Property Development Limited, Stevenage (GB)
Filed by GlaxoSmithKline Intellectual Property Development Limited, Stevenage (GB)
Filed on Aug. 22, 2023, as Appl. No. 18/453,404.
Application 18/453,404 is a continuation of application No. 16/646,875, abandoned, previously published as PCT/IB2018/056968, filed on Sep. 12, 2018.
Claims priority of provisional application 62/558,593, filed on Sep. 14, 2017.
Prior Publication US 2024/0009307 A1, Jan. 11, 2024
Int. Cl. C07K 16/28 (2006.01); A61K 31/454 (2006.01); A61K 31/573 (2006.01); A61K 39/395 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01)

CPC C07K 16/2878 (2013.01) [A61K 31/454 (2013.01); A61K 31/573 (2013.01); A61K 39/39558 (2013.01); A61K 47/68031 (2023.08); A61K 47/6817 (2017.08); A61K 47/6849 (2017.08); A61P 35/00 (2018.01)]

20 Claims

1. A method of treating relapsed/refractory multiple myeloma in a human subject that has been treated with at least one prior cancer treatment, the method comprising administering to the human subject:

1.9 mg/kg, 2.5 mg/kg, or 3.4 mg/kg of an anti-BCMA antibody-drug conjugate on day 1 of a 28-day cycle; wherein the anti-BCMA antibody drug conjugate comprises an antibody comprising the heavy chain amino acid sequence set forth in SEQ ID NO: 9 and the light chain amino acid sequence set forth in SEQ ID NO: 10, and wherein the antibody is conjugated to MMAF;

4 mg of pomalidomide on days 1-21 of the 28-day cycle; and 20 mg or 40 mg of dexamethasone on days 1, 8, 15, and 22 of the 28-day cycle.